SCHEMBL5607186

SCHEMBL5607186

Cc1ccc(Oc2ccc([N+](=O)[O-])cc2-c2ncon2)c(O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.41
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
KDM4E B2RXH2 1/20 0.38
ALOX12 P18054 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
HTT P42858 1/20 0.38
MAPT P10636 3/20 0.37
PIK3CD O00329 1/20 0.37
THRB P10828 1/20 0.37
TDP1 Q9NUW8 2/20 0.37
GAA P10253 1/20 0.36
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
TBXA2R P21731 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5607036 0.80 CASP6 (0.41) KMT2AMEN1MAPTNPC1RAB9A
SCHEMBL5606904 0.79 TTR (0.41) TTRKMT2AMEN1KDM4EALOX12
SCHEMBL5607695 0.79 KDM4E (0.65) TTRKMT2AMEN1KDM4EALOX12
SCHEMBL28407781 0.78 TDP1 (0.57) KMT2AMEN1KDM4EALOX12KDM4C
SCHEMBL28415069 0.77 GPR35 (0.47) KMT2AMEN1KDM4EALOX12KDM4C
SCHEMBL5607392 0.76 HTT (0.48) KMT2AMEN1HTTMAPTGAA
SCHEMBL5613924 0.74 KMT2A (0.43) TTRKMT2AMEN1KDM4EALOX12
SCHEMBL28410086 0.72 NPC1 (0.42) KMT2AMEN1ALOX12MAPTTDP1
SCHEMBL5606789 0.72 HSPB1 (0.52) TTRKMT2AMEN1HTTMAPT
SCHEMBL5606572 0.72 AR (0.40) TTRKMT2AMEN1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP claimed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US claimed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO claimed
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP disclosed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US disclosed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents TYR, NFE2L2, CYP1A1 TTR 4114/4885KMT2A 3809/4885MEN1 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.